Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic immune tolerizing regimen in treatment-naïve MPS II patients receiving ELAPRASE
NCT05494593Phase 4Withdrawn
- Sponsor
- Takeda
- Start
- Feb 2023
- Primary completion
- Aug 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of idursulfase in mucopolysaccharidosis type II, sponsored by Takeda. Primary endpoint: Rate of Anti-Idursulfase Antibodies Formation, Including Anti-Idursulfase Antibodies That Have Enzyme Neutralizing Activity at 24 months. Planned start Feb 2023; status: withdrawn.
02
Drugs
idursulfase
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT05494593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494593.